No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper

American Journal on Addictions

Volumn 24, Issue 4, 2015, Pages 323-328

  Epstein, David H ^a   Preston, Kenzie L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; METHADONE; MEDICAL CANNABIS; NARCOTIC AGENT;

ADULT; AGED; ARTICLE; CANNABIS SMOKING; CANNABIS USE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HEROIN DEPENDENCE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SELF MEDICATION; URINALYSIS; WITHDRAWAL SYNDROME; COCAINE-RELATED DISORDERS; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

ADULT; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MEDICAL MARIJUANA; METHADONE; MIDDLE AGED; NARCOTICS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84929044647     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12183     Document Type: Article

References (22)

1. Scavone JL, Sterling RC, Van Bockstaele EJ,. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637-654.
2. Scavone JL, Sterling RC, Weinstein SP, et al. Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict. 2013;22:344-351.
3. Birch EA,. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. The Lancet. 1889;133:625.
4. Raby WN, Carpenter KM, Rothenberg J, et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18:301-308.
5. Gossop M, Battersby M, Strang J,. Self-detoxification by opiate addicts: A preliminary investigation. Br J Psychiatry. 1991;159:208-212.
6. Noble A, Best D, Man LH, et al. Self-detoxification attempts among methadone maintenance patients: what methods and what success? Addict Behav. 2002;27:575-584.
7. Epstein DH, Schmittner J, Umbricht A, et al. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend. 2009;101:92-100.
8. Zachary R,. Shipley Institute of Living Scale. Revised Manual. Los Angeles: Western Psychological Services; 1986.
9. Kolb L, Himmelsbach CK,. Clinical studies of drug adduction, III: A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry. 1938;94:759-799.
10. Gilman AG, Goodman LS, Roll TW, Murad F,. The Pharmacological Basis of Therapeutics. New York: McMillan; 1985.
11. Preston KL, Bigelow GE, Liebson IA,. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther. 1988;246:441-448.
12. Huestis MA, Mitchell JM, Cone EJ,. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol. 1995;19:443-449.
13. Smith-Kielland A, Skuterud B, Morland J,. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999;23:323-332.
14. Rosnow RL, Rosenthal R,. Computing contrasts, effect sizes, and counternulls on other people's published data: General procedures for research consumers. Psychol Methods. 1996;1:331-340.
15. Rosnow RL, Rosenthal R, Rubin DB,. Contrasts and correlations in effect-size estimation. Psychol Sci. 2000;11:446-453.
16. Colegrave N, Ruxton GD,. Confidence intervals are a more useful complement to nonsignificant tests than are power calculations. Behav Ecol. 2003;14:446-450.
17. Zuardi AW,. History of cannabis as a medicine: A review. Rev Bras Psiquiatr. 2006;28:153-157.
18. United Nations Office on Drugs and Crime. World Drug Report. Vienna: United Nations; 2013.
19. Degenhardt L, Chiu WT, Sampson N, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. PLoS Med. 2008;5:e141.
20. Epstein DH, Preston KL,. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98:269-279.
21. Ren Y, Whittard J, Higuera-Matas A, et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009;29:14764-14769.
22. Negus SS, Banks ML,. Medications development for opioid abuse. Cold Spring Harb Perspect Med. 2014;3:a012104.